COVID-19 in a Down Syndrome Newborn

Pontes, Gabriela Caroline Lobato; Lobato, Ariella Cristina Rego; Silva, Samela Miranda da; Silva, Daniel Figueiredo Alves da; Silva, Alexandre Ferreira da; Rocha, Rodrigo Santiago Barbosa; Oliveira, Bianca Duarte de; Martins, Tallita Olga Calvinho; Chermont, Aurimery Gomes; Cunha, Katiane da Costa

doi:10.14740/ijcp396

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age of the patients was 24.8 years (26 days to 60 years), and 29 of the 55 patients were male (Supporting Information S1: Table ) 13–28 . Comorbid conditions were described for 51 cases.…”

Section: Resultsmentioning

confidence: 99%

“…The mean age of the patients was 24.8 years (26 days to 60 years), and 29 of the 55 patients were male (Supporting Information S1: Table 1 ). 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 Comorbid conditions were described for 51 cases. Obesity was the most common comorbid condition reported (49.0%, 25) followed by hypothyroidism (21.6%, 11) (Figure 1 , Supporting Information S1: Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 in patients with Down syndrome: A systematic review

Pitchan Velammal,

Balasubramanian,

Ayoobkhan

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionDown syndrome (DS) is associated with multiple comorbid conditions and chronic immune dysfunction. Persons with DS who contract COVID‐19 are at high risk for complications and have a poor prognosis. We aimed to study the clinical symptoms, laboratory and biochemical profiles, radiologic findings, treatment, and outcomes of patients with DS and COVID‐19.MethodWe systematically searched PubMed, MEDLINE, Web of Science, Scopus, and the Cochrane Library using the keywords COVID‐19 or coronavirus or SARS‐CoV‐2 and DS or trisomy 21. Seventeen articles were identified: eight case reports and nine case series published from December 2019 through March 2022, with a total of 55 cases.ResultsPatients averaged 24.8 years (26 days to 60 years); 29 of the patients were male. The most common symptoms were fever, dyspnea, and cough. Gastrointestinal and upper respiratory tract symptoms were commonly reported for pediatric patients. The most common comorbidities present in patients with DS were obesity (49.0%), hypothyroidism (21.6%) and obstructive sleep apnea (15.6%). The patients were hospitalized for a mean of 14.8 days. When the patients were compared with the general COVID‐19 population, the mean number of hospitalized days was higher. Most patients had leukopenia, lymphopenia, and elevated inflammatory markers (d‐dimer and C‐reactive protein). Bilateral infiltrations and bilateral ground‐glass opacifications were frequently seen in chest radiographs and chest computed tomographic imaging. Most of the patients were treated with methylprednisolone, macrolides, and hydroxychloroquine. Of the 55 patients, 22 died. The mean age of the patients who died was 42.8 years. Mortality rate was higher in individuals with DS over 40 years of age.ConclusionMore studies are needed to better understand COVID‐19 infections among persons with DS. In addition, the study was limited by a lack of statistical analyses and a specific comparison group.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

COVID‐19 in patients with Down syndrome: A systematic review

Pitchan Velammal,

Balasubramanian,

Ayoobkhan

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

Specific Susceptibility to COVID-19 in Adults with Down Syndrome

Illouz

Biragyn²,

Frenkel‐Morgenstern

et al. 2021

Neuromol Med

View full text Add to dashboard Cite

The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer’s disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.

show abstract

Possible factors contributing to chromosomal nondisjunction and formation of trisomic HSA21

Ganguly

2022

Genetics and Neurobiology of Down Syndrome

View full text Add to dashboard Cite

COVID-19 in a Down Syndrome Newborn

Cited by 3 publications

References 0 publications

COVID‐19 in patients with Down syndrome: A systematic review

COVID‐19 in patients with Down syndrome: A systematic review

Specific Susceptibility to COVID-19 in Adults with Down Syndrome

Possible factors contributing to chromosomal nondisjunction and formation of trisomic HSA21

Contact Info

Product

Resources

About